Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Working Capital Changes (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Other Working Capital Changes for 8 consecutive years, with -$89000.0 as the latest value for Q1 2025.

  • Quarterly Other Working Capital Changes rose 29.37% to -$89000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$89000.0 through Dec 2025, up 96.84% year-over-year, with the annual reading at $518706.0 for FY2025, 118.43% up from the prior year.
  • Other Working Capital Changes for Q1 2025 was -$89000.0 at Whitehawk Therapeutics, up from -$208000.0 in the prior quarter.
  • The five-year high for Other Working Capital Changes was $1.6 million in Q4 2022, with the low at -$3.6 million in Q4 2023.
  • Average Other Working Capital Changes over 5 years is -$304235.3, with a median of -$89000.0 recorded in 2025.
  • The sharpest move saw Other Working Capital Changes skyrocketed 20512.5% in 2022, then tumbled 1467.39% in 2023.
  • Over 5 years, Other Working Capital Changes stood at -$8000.0 in 2021, then surged by 20512.5% to $1.6 million in 2022, then crashed by 320.64% to -$3.6 million in 2023, then surged by 94.23% to -$208000.0 in 2024, then soared by 57.21% to -$89000.0 in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$89000.0, -$208000.0, and -$2.4 million for Q1 2025, Q4 2024, and Q3 2024 respectively.